Register entry

argenx BV

Data as of · How to read this entry

Registered sites
1
Active NDC listings
3
Live patents
0
Countries
1
Base
Belgium
Sites

Registered establishments

1
EstablishmentAddressRegistered forFEI / DUNS
argenx BVIndustriepark Zwijnaarde 7, Gent, 9052, Belgium (BEL)Finished drug manufacture3015102398400523378
Catalogue

Drug listings by form and route

3

3 active NDC listings: 3 human prescription drug. By marketing category: BLA 3.

Dosage formNDCs
injection, solution2
injection1
RouteNDCs
subcutaneous2
intravenous1
Labeller name on the listingNDCs
argenx us3
Catalogue

Marketed products

3
BrandGeneric nameForm / routeNDC
VYVGARTEFGARTIGIMOD ALFAinjection, intravenous73475-3041BLA
VYVGART Hytruloefgartigimod alfa and hyaluronidase (human recombinant)injection, solution, subcutaneous73475-1221BLA
VYVGART Hytruloefgartigimod alfa and hyaluronidase (human recombinant)injection, solution, subcutaneous73475-3102BLA
Compare

Comparable companies in Belgium

Enquiry

Common questions

Is argenx BV FDA approved?
argenx BV holds 1 FDA-registered establishment in Belgium. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
Where are argenx BV's drugs manufactured?
The FDA register lists Gent. Registered operations: finished drug manufacture.
What drugs does argenx BV make?
3 products are listed under argenx BV in the openFDA NDC Directory, most often as injection, solution; injection. The full breakdown by dosage form and route is above. A listing count is not a sales figure.

Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.